Composition: Glipizide Tablets IP 5 mg — each uncoated tablet contains Glipizide IP 5 mg.
Gynoglid: Glipizide Tablets BP 5 mg — each uncoated tablet contains Glipizide BP 5 mg.
Usage: Helps improve blood glucose control in adults with type 2 diabetes, along with diet and exercise.
Category: Anti Diabetic Drugs
Therapeutic Category: Antidiabetic
SKU: Glipizide Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Glipizide Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Healthy Life Pharma Pvt. Ltd. presents Glipizide Tablets, a second-generation sulfonylurea used alongside diet and exercise for glycaemic control in adults with type 2 diabetes. Glipizide stimulates insulin secretion from pancreatic beta cells. The supplied product compositions confirm uncoated 5 mg immediate-release tablets in IP and BP variants.
Manufactured by: Healthy Life Pharma Pvt. Ltd. (WHO-GMP Certified)
Exported by: Healthy Inc (Star Export House)
| Variant | Composition per tablet | Dosage form |
|---|---|---|
| Glipizide Tablets IP 5 mg | Glipizide IP 5 mg | Uncoated tablet |
| Gynoglid / Glipizide Tablets BP 5 mg | Glipizide BP 5 mg | Uncoated tablet |
Generic name: Glipizide; CAS: 29094-61-9; Therapeutic class: Sulfonylurea antidiabetic. 10 mg and extended-release variants: mentioned in background description but not confirmed by supplied compositions. Packaging, shelf life and exact pharmacopoeial specifications should be checked against the approved product dossier.
Manufacture of immediate-release glipizide tablets requires suitable control of blending, content uniformity, tablet compression and disintegration/dissolution. Modified-release systems such as osmotic or matrix tablets are separate formulations and should not be presented as manufacturing features of these confirmed uncoated 5 mg tablets without product-specific evidence.
Relevant product testing includes identification, assay, content uniformity, dissolution, impurities and stability according to the applicable approved IP or BP specification. Numeric limits and bioequivalence claims should be supported by product-specific test reports and regulatory documentation.
Glipizide binds to sulfonylurea receptors on pancreatic beta cells, closing ATP-sensitive potassium channels and promoting insulin release. It is prescribed for selected adults with type 2 diabetes when lifestyle measures alone do not provide adequate glucose control. Insulin release is not strictly meal-dependent: hypoglycaemia remains possible even when food is missed. Older adults and people with renal or hepatic impairment require particular caution.
For export and contract-manufacturing enquiries, request the product-specific certificate of analysis, manufacturing and quality documentation, stability information, and CTD/ACTD or other registration materials where available. Certificates, regulatory approvals and shipping options depend on the exact product and destination market.
Q: Which strengths are confirmed?
A: Glipizide IP 5 mg and Gynoglid / Glipizide BP 5 mg, both uncoated tablets.
Q: Is Glipizide the same ingredient as Glucotrol?
A: Glipizide is the active ingredient used in some Glucotrol products; therapeutic equivalence of a particular generic product must be established under applicable regulatory requirements.
Q: Can glipizide cause low blood sugar?
A: Yes. Severe hypoglycaemia can occur, especially if meals are skipped or doses are inappropriate.
Q: Are extended-release tablets included?
A: No verified extended-release composition was supplied for this product page.
Follow the prescription and approved label. Immediate-release glipizide is commonly taken before meals, but timing and dose must be individualized by a clinician. Extended-release tablets follow different instructions and must not be substituted without medical guidance. Never change the prescribed dose independently.
Store in a dry place in the original container, protected from excessive heat and moisture, according to the approved pack label. Keep out of reach of children.